Bone Biologics Corporation (BBLG)
After hours:
- GlobeNewswire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4cbVF5U The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download in
- Business Wire
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
BURLINGTON, Mass., June 20, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration.
- GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20th, 2024. This event is co-sponsored by Zack’s Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4bUev
